Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia

D. Sommariva, D. Bonfiglioli, M. Tirrito, I. Pogliaghi, A. Branchi, E. Cabrini

Research output: Contribution to journalArticle

Abstract

This study was carried out to evaluate the effect of the combined probucol and cholestyramine treatment on the lipoprotein pattern of hypercholesterolemic patients. Probucol was given in the dose of 1 g and cholestyramine in the dose of 16 g per day in 3 different sequences: Probucol, Cholestyramine, Probucol + Cholestyramine; Probucol + Cholestyramine, Probucol, Cholestyramine; Cholestyramine, Probucol + Cholestyramine, Probucol. After a period of dietary stabilization, 12 patients were randomly allocated to one of the treatment sequences to be followed for 9 months. Each treatment period lasted 3 months. During the cholestyramine period serum cholesterol decreased on the average by 18% and LDL cholesterol by 26%; during probucol, the mean decrease was 13% and 14%, and during the combined therapy 26% and 32%, respectively. Serum triglycerides and VLDL cholesterol showed a trend toward an increase during the cholestyramine period. HDL2 cholesterol significantly decreased during probucol treatment. Variation in both VLDL and HDL2 cholesterol observed when the drugs were given singly were no longer seen during the combination therapy.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume24
Issue number9
Publication statusPublished - 1986

Fingerprint

Probucol
Cholestyramine Resin
Hypercholesterolemia
Therapeutics
VLDL Cholesterol
HDL Cholesterol
Serum
LDL Cholesterol
Lipoproteins
Stabilization
Cholesterol

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia. / Sommariva, D.; Bonfiglioli, D.; Tirrito, M.; Pogliaghi, I.; Branchi, A.; Cabrini, E.

In: International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 24, No. 9, 1986, p. 505-510.

Research output: Contribution to journalArticle

Sommariva, D. ; Bonfiglioli, D. ; Tirrito, M. ; Pogliaghi, I. ; Branchi, A. ; Cabrini, E. / Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia. In: International Journal of Clinical Pharmacology Therapy and Toxicology. 1986 ; Vol. 24, No. 9. pp. 505-510.
@article{e2ff48b3ce82479d8d8ca66f5c399970,
title = "Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia",
abstract = "This study was carried out to evaluate the effect of the combined probucol and cholestyramine treatment on the lipoprotein pattern of hypercholesterolemic patients. Probucol was given in the dose of 1 g and cholestyramine in the dose of 16 g per day in 3 different sequences: Probucol, Cholestyramine, Probucol + Cholestyramine; Probucol + Cholestyramine, Probucol, Cholestyramine; Cholestyramine, Probucol + Cholestyramine, Probucol. After a period of dietary stabilization, 12 patients were randomly allocated to one of the treatment sequences to be followed for 9 months. Each treatment period lasted 3 months. During the cholestyramine period serum cholesterol decreased on the average by 18{\%} and LDL cholesterol by 26{\%}; during probucol, the mean decrease was 13{\%} and 14{\%}, and during the combined therapy 26{\%} and 32{\%}, respectively. Serum triglycerides and VLDL cholesterol showed a trend toward an increase during the cholestyramine period. HDL2 cholesterol significantly decreased during probucol treatment. Variation in both VLDL and HDL2 cholesterol observed when the drugs were given singly were no longer seen during the combination therapy.",
author = "D. Sommariva and D. Bonfiglioli and M. Tirrito and I. Pogliaghi and A. Branchi and E. Cabrini",
year = "1986",
language = "English",
volume = "24",
pages = "505--510",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0174-4879",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "9",

}

TY - JOUR

T1 - Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia

AU - Sommariva, D.

AU - Bonfiglioli, D.

AU - Tirrito, M.

AU - Pogliaghi, I.

AU - Branchi, A.

AU - Cabrini, E.

PY - 1986

Y1 - 1986

N2 - This study was carried out to evaluate the effect of the combined probucol and cholestyramine treatment on the lipoprotein pattern of hypercholesterolemic patients. Probucol was given in the dose of 1 g and cholestyramine in the dose of 16 g per day in 3 different sequences: Probucol, Cholestyramine, Probucol + Cholestyramine; Probucol + Cholestyramine, Probucol, Cholestyramine; Cholestyramine, Probucol + Cholestyramine, Probucol. After a period of dietary stabilization, 12 patients were randomly allocated to one of the treatment sequences to be followed for 9 months. Each treatment period lasted 3 months. During the cholestyramine period serum cholesterol decreased on the average by 18% and LDL cholesterol by 26%; during probucol, the mean decrease was 13% and 14%, and during the combined therapy 26% and 32%, respectively. Serum triglycerides and VLDL cholesterol showed a trend toward an increase during the cholestyramine period. HDL2 cholesterol significantly decreased during probucol treatment. Variation in both VLDL and HDL2 cholesterol observed when the drugs were given singly were no longer seen during the combination therapy.

AB - This study was carried out to evaluate the effect of the combined probucol and cholestyramine treatment on the lipoprotein pattern of hypercholesterolemic patients. Probucol was given in the dose of 1 g and cholestyramine in the dose of 16 g per day in 3 different sequences: Probucol, Cholestyramine, Probucol + Cholestyramine; Probucol + Cholestyramine, Probucol, Cholestyramine; Cholestyramine, Probucol + Cholestyramine, Probucol. After a period of dietary stabilization, 12 patients were randomly allocated to one of the treatment sequences to be followed for 9 months. Each treatment period lasted 3 months. During the cholestyramine period serum cholesterol decreased on the average by 18% and LDL cholesterol by 26%; during probucol, the mean decrease was 13% and 14%, and during the combined therapy 26% and 32%, respectively. Serum triglycerides and VLDL cholesterol showed a trend toward an increase during the cholestyramine period. HDL2 cholesterol significantly decreased during probucol treatment. Variation in both VLDL and HDL2 cholesterol observed when the drugs were given singly were no longer seen during the combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=0022504908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022504908&partnerID=8YFLogxK

M3 - Article

C2 - 3781686

AN - SCOPUS:0022504908

VL - 24

SP - 505

EP - 510

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0174-4879

IS - 9

ER -